Common TitleHBV-16: Heplisav-B versus Engerix-B in Healthy Adults 40-70 Years of Age
Official Title An Observer-Blinded, Randomized, Parallel-Group, Multi-Center Study Comparing the Safety and Immunogenicity of HEPLISAV™ to Licensed Vaccine (Engerix-B®) Among Healthy Subjects 40 to 70 Years of Age
Phase Phase III
ClinicalTrials.gov NCT01005407
Treatments
Heplisav-B
Heplisav-B
Tradename:Heplisav-BOther Names:Hepatitis B Vaccine (Recombinant) Adjuvanted, HepB-CpGClass:Vaccines (HBV)Funding
IndustryDynavax Technologies Corporation